Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Binge-eating disorder
- Focus Therapeutic Use
- Sponsors Shire
- 17 May 2013 Data will be presented at the American Psychiatric Association (APA) 166th Annual Meeting, according to a Shire media release.
- 06 Aug 2012 New trial record